Background. Respiratory syncytial virus (RSV) is targeted for vaccine development, because it causes severe respiratory tract illness in the elderly, young children, and infants. A primary strategy has been to derive live attenuated viruses for use in intranasally administered vaccines that will induce a protective immune response. In the present study, the NS2 gene, whose encoded protein antagonizes the host's interferon-a/b response, was deleted from RSV vaccine candidates by use of reverse genetics.
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory tract illness in the elderly, young children, and infants, and it is a priority for vaccine development [1, 2] . The primary strategy for RSV vaccine development has been to identify live attenuated RSV vaccine candidates for intranasal administration that are satisfactorily attenuated and induce a protective im-mune response in the targeted age group. The intranasal approach using live virus is based on observations that mucosal immunity plays an important role in protection against RSV infection and is optimally stimulated by intranasal immunization [3] . The original live attenuated RSV vaccine candidate was derived by passage of wild-type (wt) RSV in vitro at suboptimal temperatures, yielding the cold-passaged (cp) attenuated cpRSV strain [4] . Chemical mutagenesis of cpRSV yielded further-attenuated temperature-sensitive (ts) derivatives that are referred to as "RSVcpts" strains [5] . One strain, designated RSVcpts248/404, was evaluated in 1-2-month-old infants, which is the target group for pediatric vaccine use. In this age group, intranasal immunization induced a significant antibody response and conferred protective immunity against a second vaccine dose [6] .
RSV vaccine development became much less empirical with the introduction of reverse genetics, which allows the production of infectious RSV strains entirely from cloned cDNA transfected into tissue-culture cells [7] . The cDNA intermediate provides a means for introducing defined mutations into infectious RSV strains to make "designer" attenuated vaccine candidates [7] . The attenuating mutations in the lineage of cpRSV and RSVcpts strains were identified using reverse genetics [8] , and new attenuating mutations were created by deletion of nonessential accessory genes, including the small hydrophobic (SH) surface protein, the M2 protein involved in regulating RNA synthesis, and the nonstructural (NS) 1 and NS2 nonstructural proteins, which are described in more detail below [9] .
Reverse genetics was used to combine the attenuating mutations from the above-mentioned RSVcpts248/404 strain with a point mutation (designated 1030) from another strain, along with a deletion of the SH gene. The resulting recombinant strain, rA2cp248/404/1030DSH, was well tolerated and immunogenic in 1-2-month-old infants, although some of the viral samples that were recovered from recipients exhibited the loss of a single attenuating point mutation [10] , suggesting that greater genetic stability was desirable. Gene deletions are particularly attractive stabilizing genetic mutations, because they presumably cannot undergo reversion during the limited duration of in vivo replication that is characteristic of RSV. Attenuation resulting from a gene deletion identifies the deleted gene product as an important virulence factor.
Proteins encoded by many virus genes have been found to antagonize the effects of the host's interferon (INF)-a/b response, which functions to suppress viral growth in the early stages of infection before the adaptive immune response comes into play [11] . Suppression of the INF response is achieved by a decrease in the production of INF, by a decrease in the antiviral effects generated after interaction of INF with its receptor, or by both processes. The RSV nonstructural proteins NS1 and NS2 suppress the production of INF-a/b and also suppress the cell's ability to establish an antiviral state [12] [13] [14] . Deletion of either the NS1 or the NS2 gene attenuates human or bovine RSV in chimpanzees or cattle, respectively [15, 16] . The role of these INF antagonists in the virulence of RSV in humans remains undefined.
In the present study, the NS2 gene was deleted to generate a vaccine candidate (rA2cpDNS2) for use in the elderly. Because RSVcpts248/404 had been found to be poorly infectious and immunogenic in RSV-experienced subjects [17] , a vaccine for this population was sought that would be less attenuated than RSVcpts248/404. In a previous study, deletion of the NS2 gene yielded a strain that was less attenuated in chimpanzees than was RSVcpts248/404 [16] , whereas deletion of the NS1 gene yielded a strain that was more attenuated [18] . Reverse genetics was used to construct the recombinant RSV vaccine candidate rA2cpDNS2, which contains the set of 5 mutations in the attenuated cpRSV parent strain and lacks the NS2 gene. In primate models, the recombinant cpRSV strain exhibited the same growth properties as its biologically derived parent [19] .
Additionally, we evaluated 2 mutants as vaccine candidates for RSV-seronegative children. For this use, the NS2 gene was deleted from recombinant versions of 2 RSVcpts vaccine candidates that previously were incompletely attenuated in RSV-seronegative children (RSVcpts530/1009 [20] ) or in RSV-seronegative infants (RSVcpts248/404 [6] ). These vaccine candidates, rA2cp248/ 404DNS2 and rA2cp530/1009DNS2, were evaluated for safety, infectivity, and immunogenicity in RSV-seropositive and RSVseronegative children.
SUBJECTS, MATERIALS, AND METHODS

Viruses.
The 3 NS2 gene-deleted strains examined in the present study-rA2cpDNS2, rA2cp248/404DNS2, and rA2cp530/ 1009DNS2-were derived using techniques described elsewhere [18, 21] . Each strain contained the 5 cp mutations present in cpRSV. This constellation of mutations is found in the nucleocapsid (N) gene encoding the nucleocapsid protein, the large (L) gene encoding the polymerase protein, and the gene encoding the fusion (F) glycoprotein [10] . The NS2 gene was deleted by removing nt 577-1098, thereby joining the NS1 gene end to the NS2-N intergenic region. The 530 and 1009 L-gene amino acid mutations were introduced into the rA2cp530/ 1009DNS2 construct and had 2 nucleotide changes each, rather than the single nucleotide change found in the biologically derived strain, to reduce the possibility of reversion of this codon to the wt form. Virus rescues and all terminal dilution and amplification passages were performed in Vero cells. Clinical trial material was produced in Vero cells and was found to be free of adventitious agents by Wyeth Vaccines Research (Pearl River, NY).
Clinical studies in adults. Each vaccine candidate was initially evaluated in adults at a dose of 10 5.0 pfu, delivered in intranasal drops. An unblinded experimental design was used, with clinical assessment on days 4-8. Serum samples were collected before immunization and 28 days after immunization, to measure immune responses to vaccines. Adults were not prescreened or selected for low RSV-specific antibody titers. rA2cpDNS2 was also tested at doses of 10 6.0 and 10 7.0 pfu. Clinical studies in RSV-seropositive children. After evaluation in adults, each NS2 gene-deleted vaccine candidate was administered to children 15-59 months old with preexisting immunity to RSV. Children were enrolled in randomized, double-blind, placebo-controlled studies with a 2:1 ratio of vaccine:placebo recipients. Children were eligible to participate if they were healthy and if all other family members and day care contacts were у6 months old. Before enrollment, children were screened for the presence of serum RSV-neutralizing antibodies by use of a 60% plaque-reduction neutralization test without the addition of complement [20] . Children with antibody titers 11:40 were considered to be RSV seropositive and suitable for inclusion in the trial. Each child received 10 5.0 pfu of vaccine or a saline placebo delivered in intranasal drops. Children were assessed clinically for 1-2 h on days 3-7 and on days 9 and 10 in an outpatient setting. Febrile illness was defined as a rectal temperature у38ЊC. Respiratory tract illness was categorized as either upper respiratory tract illness (URTI), which was defined as rhinorrhea or pharyngitis of у2 consecutive days in duration, or lower respiratory tract illness (LRTI), which was defined as persistent rhonchi, rales, or wheezing. Cough for у2 consecutive days was recorded without assigning a site of respiratory tract involvement.
Clinical studies in RSV-seronegative children. Because of satisfactory safety profiles and limited shedding of rA2cp248/ 404DNS2 and rA2cp530/1009DNS2 by RSV-seropositive children when administered a dose of 10 5.0 pfu, these 2 vaccine candidates at the same dose were evaluated in RSV-seronegative children 6-24 months old. RSV-seronegative children were examined on days 0, 3, 5, 7, 8 or 9, 10, 12, 14, and 21. The same clinical assessment and definitions of illness that were applied to RSV-seropositive children were applied to RSV-seronegative children. Clinical studies in all age groups were performed during the summer (April-October in the Northern Hemisphere and October-April in the Southern Hemisphere), to avoid natural exposure to circulating wt RSV.
Isolation, quantitation, and identification of RSV. Nasal wash samples were obtained on each day of observation, for assessment of virus isolation. Additional samples were collected when respiratory tract or febrile illness was reported during the 3 weeks after immunization, as described elsewhere [20] . Fresh or snap-frozen samples were inoculated into 2 sets of tissueculture tubes containing Vero or HEp-2 cell monolayer cultures and were incubated at 32ЊC. Viral isolates from these cultures were identified as RSV by use of an indirect immunofluorescence assay (Bartels Microscan; Baxter Healthcare). The quantity of RSV in snap-frozen samples was determined by titration in a plaque assay performed with HEp-2 or Vero cell monolayer cultures maintained under a semisolid overlay at 32ЊC, as described elsewhere [20] . Virus titers were expressed as log 10 plaque-forming units per milliliter of nasal wash fluid. Samples in which virus was not detected were assigned a titer of 0.3 log 10 pfu/mL, for the purpose of determining means.
Phenotypic and genetic characterization of virus isolates. The plaque size of virus isolates was assessed by comparison with the plaque size and morphological characteristics of the rA2cpDNS2 reference strain (small pinpoint plaque phenotype) [21] and the wt RSV A2 strain (large-plaque phenotype) after growth in HEp-2 cells at 32ЊC. To test for the presence of NS2 gene-deleted RSV strains in vaccine recipients, viral genome sequences were amplified directly from nasal wash samples by use of reverse-transcription polymerase chain reaction (PCR) with primers from conserved regions in the NS1 and N genes; this yielded a 853-bp PCR product from RSV strains containing the NS2 gene and a 325-bp PCR product from NS2 gene-deleted RSV strains. All nasal wash samples from recipients of rA2cpDNS2 were tested for RSV by a quantitative real-time PCR that was performed using RSV A-and RSV B-specific probes, as described elsewhere [22] . The presence of the ts phenotype in nasal wash samples and in virus isolates was tested in recipients of rA2cp248/404DNS2, as described elsewhere [6] .
Adventitious agents. Nasal wash samples were cultured for adventitious agents by inoculating samples collected from ill patients onto a fibroblast line (WI38 or MRC), human cell lines (human neonatal kidney or HEp-2), and primary or continuous monkey kidney cells, as described elsewhere [20] .
Immunologic assays. Serum samples were obtained before and 4 weeks after immunization, to measure RSV-specific antibodies. Serum samples were tested for antibodies to RSV by use of a complement-enhanced, 60% plaque-reduction neutralization assay [23] and for IgG and IgA antibodies to RSV F and attachment (G) glycoproteins by use of an end-point titration in an ELISA [19] . The results were expressed as reciprocal log 2 titers, and a positive immune response was defined as a у4-fold increase in antibody titers.
Nasal wash samples were obtained from RSV-seronegative children and tested for the presence of IgA antibodies to purified RSV F and G glycoproteins by use of a kinetic ELISA (kELISA) that was originally developed for influenza virus [24] . The increase in the IgA antibody titer, which was defined as the change in OD units over time (expressed per 1000 OD units/min [mOD/min] with absorbance at 414 nm), in each nasal wash sample was expressed as a dilution of a standard serum curve control in the assay. Samples with kELISA values !5 mOD/min were defined as being negative. For preimmunization and postimmunization samples in which RSV-specific antibody was detected, values for the RSV-specific titers were normalized for their total IgA titers. Replicate experiments determined that a у4-fold difference in the standardized, ad-justed result was outside the 95% confidence interval for the test. Therefore, changes of this magnitude between titers in paired preimmunization and postimmunization samples or between paired samples for which there was a change from a negative to a positive result were considered to indicate that a mucosal antibody response had developed after the administration of the vaccine.
Data analysis. Infection after immunization with an RSV vaccine was defined as isolation of RSV and/or a у4-fold increase in serum RSV-neutralizing antibody titers and/or a у4 increase in antibody titers measured in у2 ELISA-based assays. In children !6 months old with residual maternal antibodies at the time of immunization, an increase was calculated as a value that was 4-fold higher than the anticipated value when the 28-day decrease in passive antibody titers was taken into account.
After analysis, the serostatus of a limited number of children was redefined after definitive antibody testing was performed using a complement-enhanced assay. For the purposes of analysis, these children were reassigned to the appropriate serostatus groups. This led to the inclusion of 6 children aged !15 months in the RSV-seropositive group (the age range was initially 15-59 months for this group); 1 child aged 7 months in the rA2cp248/404DNS2 group; 3 children aged 7, 11, and 13 months in the rA2cp530/1009DNS2 group; and 2 children aged 10 and 11 months in the placebo group. One child in the rA2cp248/404DNS2 group who had intercurrent wt RSV was excluded from the analysis. Serum antibody titers were expressed as reciprocal mean log 2 values. The Mann-Whitney U test (2-tailed) was used to compare the mean titers between the groups. Comparison of tabulated data (for example, frequency of illness or immune responses) was made using a 2-tailed Fisher's exact test. (table 2) . Antibody titers in nasal wash samples were measured only in adults who received 10 5.0 pfu of rA2cpDNS2. Four (19%) of 21 adults had an increase in the titers of IgA antibodies to either F or G glycoprotein in their nasal wash samples (data not shown). When these results were compared with those in previous studies, it was found that deletion of the NS2 gene significantly attenuated the biologically derived cpRSV parent strain [4] for adults, as was indicated by a decrease in the frequency that rA2cpDNS2 was shed (table 3). The methodologies that were used in the present study to determine viral shedding, immune responses, and vaccine safety were unchanged from those used in previous studies [4, 6, 10, 20, 25] .
RESULTS
Adults
Only low, background levels of illness were observed in adults. Because each of the 3 vaccine candidates had acceptable safety profiles after use in adults (table 1), as was expected for strains with such low infectivity for this age group, these 3 RSV vaccine candidates were next tested in RSV-seropositive children.
RSV-seropositive children. rA2cpDNS2 at a dose of 10 5.0 pfu was evaluated in 8 RSV-seropositive children. Three children (38%) shed virus, with a mean peak titer of 3.4 log 10 pfu/ mL (table 1) . Two additional children had detectable virus by PCR. Each of 9 isolates detected retained the small-plaque phenotype of the rA2cpDNS2 input virus. Each of 5 isolates tested were shown to have a full deletion of the NS2 gene. The higher level of viral shedding by RSV-seropositive children than by adults indicated that RSV-seropositive children were more susceptible to rA2cpDNS2 than were adults (table 3) , as was previously observed in studies of cpRSV [4, 25] . Immune responses in children who received rA2cpDNS2 were seen only in those shedding virus (table 1) . Separate groups of RSV-seropositive children received rA2cp248/404DNS2 or rA2cp530/1009DNS2 at a dose of 10 5.0 pfu. Viral shedding was not detected in any of the children who received rA2cp530/1009DNS2, and only a low level of viral shedding was detected in 1 child (6%) who received rA2cp248/ 404DNS2 (table 1) . In a previous study, only minimal shedding of the RSVcpts248/404 and RSVcpts530/1009 parent strains was observed in RSV-seropositive children [6, 20] . No immune responses were observed in 16 children who received rA2cp248/ 404DNS2 or in 4 children who received rA2cp530/1009DNS2 and for whom paired serum samples were available (table 2) . Illness was seen in temporal association with shedding of adventitious virus (table 1), but illness was not seen in temporal association with shedding of vaccine virus.
In summary, because rA2cpDNS2 at a dose of 10 5.0 pfu replicated efficiently in RSV-seropositive children and because RSV strains that replicate efficiently in RSV-seropositive children can retain reactogenicity for RSV-seronegative children or infants [20] , rA2cpDNS2 was not tested in RSV-seronegative children. Because rA2cp248/404DNS2 and rA2cp530/1009DNS2 were highly attenuated in RSV-seropositive children, they were next evaluated in RSV-seronegative children.
RSV-seronegative children. In previous studies, the RSVcpts248/404 and RSVcpts530/1009 parent strains infected 80%-100% of RSV-seronegative children, with a high percentage of recipients shedding virus [6, 20] . In contrast, immunization with the same dose of rA2cp530/1009DNS2 or rA2cp248/404DNS2 resulted in viral shedding in only 20%-40% of recipients (table 1 and figure 1) . Thus, the attenuating effect of deleting the NS2 gene was clearly seen in RSV-sero- NOTE. Titers were measured before and after vaccination. An immune response was defined as a у4-fold increase in serum RSV-neutralizing antibody titers and/or a у4-fold increase in titers measured in у2 ELISA-based assays. All titers are expressed as log 2 plaque-forming units per milliliter of serum. Figure 1 . Comparison of the frequency and amount of viral shedding in respiratory syncytial virus (RSV)-seronegative children who received attenuated RSV vaccine candidates or parent strains. The no. above each bar is the mean peak viral titer (in log 10 plaque-forming units per milliliter of nasal wash fluid). Data on the biologically derived cpts530/1009 and cpts248/404 parent strains are from [6] and [19] , respectively. All in vitro and animal comparisons indicate that recombinant vaccine candidates behave in a fashion that is identical to that of their biologic parent strains [19, 26] .
negative children, as was evidenced by a decreased frequency and magnitude of viral shedding ( figure 1 ). An increase in the frequency of illness was not seen in children who received either rA2cp530/1009DNS2 or rA2cp248/404DNS2, compared with that in children who received placebo, although the frequency of illness was high in all groups (table 1) . rA2cp530/1009DNS2 appeared to be overattenuated, because only 3 (20%) of 15 children shed this strain. rA2cp248/404DNS2 appeared to be slightly more infectious, with 40% of children shedding this strain, although the titers were clearly lower than those in children who received the RSVcpts248/404 parent strain, which possesses the NS2 gene ( figure 1 ). Of 8 nasal wash samples from children who received rA2cp248/404DNS2 and shed virus, only 3 contained virus of sufficient titer for determination of the phenotype. All 3 isolates retained the ts phenotype. Immune responses paralleled viral shedding and were most consistently detected by increases in serum RSV-neutralizing antibody titers and increases in titers of IgG antibody to the F glycoprotein (table 2) . Fifty percent of children who received rA2cp248/404DNS2 were infected with RSV, compared with 20% of children who received rA2cp530/1009DNS2. IgA antibody titers were measured in nasal wash samples obtained before and after immunization with rA2cp248/404DNS2, and only 1 (13%) of 8 children with paired samples had an increase in titers.
DISCUSSION
Gene deletion offers great promise for the design of molecularly engineered live attenuated intranasal RSV vaccines. One important advantage is that an attenuating gene deletion should be a highly stable mutation, whereas most previously evaluated RSV vaccines contained point mutations that can be unstable after replication in vitro or in vivo [6, 20, 27] . rA2cpDNS2 was evaluated as a vaccine candidate for the elderly and for other RSV-seropositive individuals at risk for serious RSV disease, such as those with underlying cardiopulmonary disease [28] . A live attenuated RSV vaccine is difficult to develop for use in adults, because the vaccine must be both infectious and immunogenic for partially immune adults and safe for RSV-seronegative infants and children who may be exposed to infection through contact with adult vaccinees. Preclinical evaluation in chimpanzees indicated that a recombinant RSV strain lacking the NS2 gene had an intermediate lev- Upper respiratory tract illness (URTI) was defined as rhinorrhea or pharyngitis of у2 consecutive days in duration; lower respiratory tract illness (LRTI) was defined as persistent rhonchi, rales, or wheezing; cough for у2 consecutive days was recorded without assigning a site of involvement in the respiratory tract. In some subjects with illness, adventitious agents were isolated. There was no temporal association between recovery of an RSV vaccine strain and clinical symptoms. PIV, parainfluenza virus. b Infection with an RSV vaccine strain was defined as isolation of RSV and/or a у4-fold increase in serum RSV-neutralizing antibody titers and/or a у4-fold increase in antibody titers measured in у2 ELISA-based assays. c Rhinovirus and PIV3 were isolated from 2 adults with URTI. d Adenovirus was isolated from 1 child with URTI. e PIV1 was isolated from 1 child with fever, and adenovirus was isolated from an asymptomatic child. f PIV3 was isolated from 1 child with cough and 2 children with fever and URTI. Adenovirus was isolated from 1 of these children during a separate episode of URTI. g Although RSV was isolated from the child at the study site, the identity of the isolated virus could not be confirmed at the central laboratory, and, thus, the isolate was not characterized further. h PIV3 was isolated from 1 child with cough. i Rhinovirus was isolated from 1 asymptomatic child. j Adenovirus was isolated from 1 child with URTI and 1 asymptomatic child. PIV3 was isolated from 2 children with URTI and cough.
el of attenuation that was between that of RSVcpts248/404 [16] , which is overattenuated in adults, and that of cpRSV, which is shed by adults [4, 20] , but this strain was incompletely attenuated in RSV-seronegative infants [25] . The rA2cpDNS2 vaccine candidate was not infectious for adults at doses of 10 5.0 -10 6.0 pfu. Even at a high dose of 10 7.0 pfu, it was not shed by adults, and only 13% of them developed an immune response. Because of its low level of infectivity and weak immunogenicity, rA2cpDNS2 was considered to be overattenuated for use in a vaccine for adults. In contrast, rA2cpDNS2 was shed by RSV-seropositive children at titers of up to 4.0 log 10 pfu/mL of nasal wash. This substantial viral shedding by RSVseropositive children suggested that rA2cpDNS2 would be insufficiently attenuated in RSV-seronegative children [25] , and evaluation in that population was not performed. Two vaccine candidates, rA2cp248/404DNS2 and rA2cp530/1009DNS2, were evaluated in RSV-seronegative children. Their biologically derived parent strains, RSVcpts248/404 and RSVcpts530/1009, were highly infectious and replicated to moderate titers (14.0 log 10 pfu/mL) in RSV-seronegative children, and mild residual reactogenicity with RSVcpts248/404 was seen in infants [6, 20] . Deletion of the NS2 gene from RSVcpts248/404 and RSVcpts530/ 1009 greatly reduced both the infectivity and the level of replication of these 2 strains in RSV-seronegative children. rA2cp248/ 404DNS2 and rA2cp530/1009DNS2 were not associated with symptomatic illness in recipients, a finding that was consistent with their low level of replication (peak titer, 1.3-2.3 log 10 pfu/ mL). These findings identify the deletion of the NS2 gene as a mutation capable of further restricting the level of replication of RSVcpts248/404 and RSVcpts530/1009 in children. At a dose of 10 5.0 pfu, rA2cp248/404DNS2 and rA2cp530/1009DNS2 infected 50% and 20% of RSV-seronegative children, respectively. These values are too low for them to be acceptable for use at this dose in a vaccine, but their infectivity for RSV-seronegative subjects might be increased by increasing the dose to 10 6.0 -10 7.0 pfu or delivering the vaccine by nasal spray [29] . In summary, although the 3 RSV vaccine candidates in the present study did not have the properties of an acceptable vaccine at the doses tested, valuable information on the pathogenesis of RSV in humans was revealed. Deletion of the NS2 gene attenuated RSV for immune and nonimmune humans, a finding that clearly identifies the NS2 gene as an important determinant of virulence of RSV for humans. Although other candidate respiratory tract virus vaccines have mutations in genes that inhibit the INF response [30] , to our knowledge, deletion of the RSV NS2 gene in the present study represents the first example of attenuation that was clearly conferred by deletion of the INF antagonist for humans. The mechanism of the INF antagonism appears to be through regulation of INFa/b transcriptional factors. Specifically, NS2 and NS1 cooperatively suppress activation and nuclear translocation of INF regulatory factor-3, and NS2 reduces the capacity of RSV to induce activation of NF-kB [31] . The observation that deletion of the NS2 gene leads to attenuation of RSV for humans validates the strategy of using reverse genetics to develop RSV vaccines and provides a new approach to attenuation of live respiratory tract viruses for use in human vaccines, through modification of the ability of a virus to inhibit the innate immune system of the human host.
